SpyGlass Bimatoprost Drug Delivery Platform Improves Vision at 18 Months

Interim safety and efficacy data from the first-in-human study of the SpyGlass Drug Delivery Platform showed key improvements in vision and intraocular pressure (IOP) outcomes at 18 months in eyes with mild to moderate open-angle glaucoma or ocular hypertension.1

Presented at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, the monofocal intraocular lens (IOL) with mounted sustained-release bimatoprost implant achieved statistically and clinically significant reductions in IOP across all patient groups, with no reports of device-related adverse events.

“In the US, 5 million cataract surgeries are performed annually, with 20% occurring in patients who also have increased intraocular pressure caused by open-angle glaucoma or ocular hypertension,” said Malik Kahook, MD, co-founder of SpyGlass Pharma and a professor of ophthalmology at the University of Colorado Anschutz Medical Campus.2 “Our compelling 18-month results highlight the potential long-term benefits of the SpyGlass Drug Delivery Platform for these patients.”

A total of 23 eyes treated across 75 mcg, 150 mcg, and 300 mcg doses were included in the single-center prospective cohort study and examined at regular intervals, with a planned three-year follow-up. Investigators measured safety and efficacy using best-corrected distance visual acuity (BCDVA), IOP, and slit lamp examination.1

Upon analysis, at 18 months, the BCDVA improved from a baseline range of 20/30 to 20/100 to a range of 20/16 to 20/30, while IOP was reduced from a baseline of 25.1 ± 2.5 mmHg to 14.1 ± 2.6 mmHg (P <.0001). Investigators identified no statistically significant differences in IOP lowering across the three dosage groups, and all patients remained off topical IOP-lowering medication at the 18-month follow-up visit.

“The promising improvement in visual acuity, along with the clinically meaningful reduction in IOP, reinforce our confidence in the platform, and we look forward to sharing these data with the ophthalmic community at ASCRS,” Kahook added.2

SpyGlass completed enrollment in its US Phase 1/2 study and continues to follow patients from its first-in-human trial, with plans to share long-term data soon as it works with the US Food and Drug Administration (FDA) to advance toward Phase 3 trials and commercial approval.1

“We continue to see the SpyGlass Drug Delivery Platform poised to reimagine the treatment paradigm by addressing the unmet need of long-term drug delivery while also utilizing a familiar implantation technique for cataract surgeons,” said Patrick Mooney, chief executive officer of SpyGlass Pharma.2 “This promising dataset bolsters the potential for long-term durability of both visual outcomes and IOP-lowering efficacy. We look forward to providing further data updates from this ongoing study."

References

1. Robles MA, Robles PJ, Sussman G, Kahook MY, et al. Visual Outcomes of an Intraocular Lens with a Sustained-Release Bimatoprost Implant in Eyes with Open Angle Glaucoma or Ocular Hypertension. Presented at: 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. April 25-28, 2025. Los Angeles, CA.

2. Spyglass Pharma, Inc. Spyglass pharma presents 18-month data demonstrating compelling visual acuity results with their IOL-Mounted Innovative Drug Delivery Platform. GlobeNewswire News Room. April 24, 2025. Accessed April 25, 2025. https://www.globenewswire.com/news-release/2025/04/24/3067371/0/en/SpyGlass-Pharma-Presents-18-Month-Data-Demonstrating-Compelling-Visual-Acuity-Results-with-Their-IOL-mounted-Innovative-Drug-Delivery-Platform.html.